CAMBRIDGE, Mass. — Enveric Biosciences said it has been granted a new U.S. patent covering its EVM301 series of drug candidates, strengthening its intellectual property portfolio focused on developing treatments for psychiatric and neurological disorders.
The patent, issued March 17, 2026, by the U.S. Patent and Trademark Office, relates to a group of N-heterocycle substituted tryptamine derivatives and methods for their use. The EVM301 series includes the company’s lead candidate, EB-003, which is being developed as a potential treatment for mental health conditions.
According to the company, the newly issued patent expands protection for its neuroplastogenic molecules, which are designed to promote neuroplasticity without producing hallucinogenic effects. The patent also covers associated chemical compounds, pharmaceutical formulations, and therapeutic applications for brain-related disorders.
The ‘232 patent builds on earlier intellectual property, including a previously issued U.S. patent covering similar compounds. Enveric said its broader patent estate now includes 27 issued U.S. patents and roughly 60 pending applications globally.
“We are very pleased with this new U.S. patent issuance as we continue to work diligently to reinforce our EVM301 Series intellectual property estate and generate additional value for Enveric stockholders,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Our company remains focused on advancing EB-003 toward submitting an IND application to the FDA and initiating a first-in-human Phase 1 clinical trial.”
EB-003 is designed as a dual-acting compound targeting 5-HT2A and 5-HT1B receptors, with the goal of treating conditions such as depression and anxiety by inducing beneficial changes in brain function without hallucinogenic side effects.
Enveric said its research pipeline is aimed at addressing neuropsychiatric and addiction disorders, particularly for patients who have limited treatment options.
